PB1807 RESULTS OF TREATMENT BY REGIMENS R‐MPV/TBC FOR PATIENTS WITH PRIMARY CNS LYMPHOMA

Abstract

Background:High‐dose MTX‐containing chemotherapy and autologous stem sell transplantation (HDC‐ASCT) is a potentially curable options for patients with primary central nervous system lymphoma (PCNCL). In our prospective study, pts with newly diagnosed PCNSL were treated with R‐MPV (rituximab, methotrexate, vincristine and procarbazine) chemotherapy, followed by consolidation HDC‐ASCT with TBC (thiotepa, busulfan and cyclophosphamide). After completion of therapy all pts reseived maintenance treatment with temozolomide every 3 months for a total of 2 years.Aims:To assess the efficacy and safety of regimens R‐MPV/TBC for patients with PCNSL.Methods:A total 19 pts were enrolled in prospective study between 2015 to 2019 years. The median age was 43 years (range, 20 to 62 years), with a total of 2 (10%) ≥ 60 years of age. Male:female = 13:7. In four pts (21%) the ECOG status was ≥ 2. The MSKCC prognostic class was as follows: 17 pts (91%), class 1; 2 pts (9%), class 2; 0 pts, class 3.Results:Following 3‐5 R‐MPV cycles 16 pts were in CR and 3 pts in PR. All pts were undegro stem‐sell harvest after the second cycle. All pts eventually received HDC‐ASCT with TBC. Treatment‐related mortality was 0%. All pts achieved haemotopoietic regeneration: the median times neutrophil and platelet recovery were 9 and 14 days, respectively. Seventeen pts are alive and well in complete remission at a median follow‐up of 12 months (range 1‐40). Two pts with progressive disease (+6 months) went on to received second‐line treatment: both had received chemotherapy and WBRT.Summary/Conclusion:Regimens R‐MPV/TBC was associated with favorable safety and high preliminary efficacy.